-
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Potential efficacy of preparations derived from Phaseolus vulgaris in the control of appetite, energy intake, and carbohydrate metabolism
Commentary
(2649) Views (1150) Full article downloads
Authors: Mauro AM Carai, Noemi Fantini, Barbara Loi, et al
Published Date September 2009
Volume 2009:2 Pages 145 - 153
DOI: http://dx.doi.org/10.2147/DMSO.S4236
Mauro AM Carai1, Noemi Fantini1, Barbara Loi1, Giancarlo Colombo1, Antonella Riva2, Paolo Morazzoni2
1C.N.R. Institute of Neuroscience, Cagliari, Italy; 2Indena SpA, Milan, Italy
Abstract: Preclinical data on extracts of and preparations derived from beans of Phaseolus vulgaris are reviewed as potential remedies for use in controlling food consumption, body weight, lipid accumulation, and glycemia. A growing body of evidence suggests that acute and chronic administration of P. vulgaris derivatives reduces food intake (including highly palatable foods), body weight, lipid deposit, and glycemia in rats exposed to multiple experimental procedures. Two possible lectin-mediated mechanisms of action have been proposed: (a) inhibition of α-amylase, resulting in a reduced carbohydrate metabolism and absorption; (b) phytohemoagglutinininduced modulation of the activity of cholecystokinin and glucagon-like peptides, resulting in a reduced appetite. Preliminary clinical data, as well as reports focusing on the use of several traditional medicines, apparently extend these findings to humans. Should these initial clinical data be confirmed by future surveys, P. vulgaris derivatives might constitute novel remedies for the treatment of obesity and metabolic syndrome. Future studies are also expected to identify active structures leading to the development of new pharmaceutical agents.
Keywords: Phaseolus vulgaris extracts and derivatives, food intake, body weight, lipid accumulation, glycemia, obesity, diabetes, metabolic syndrome
Readers of this article also read:
Peroxisome proliferator-activated receptors as stimulants of angiogenesis in cardiovascular disease and diabetes
Impact of obesity and type 2 diabetes on health-related quality of life in the general population in England
Management of obesity, insulin resistance and type 2 diabetes in children: consensus and controversy
Amantadine reduces glucagon and enhances insulin secretion throughout the oral glucose tolerance test: central plus peripheral nervous system mechanisms
Type 2 diabetes mellitus and inflammation: Prospects for biomarkers of risk and nutritional intervention
Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
Effects of zinc and multimineral vitamin supplementation on glycemic and lipid control in adult diabetes
Randomized, double-blind, placebo-controlled, linear dose, crossover study to evaluate the efficacy and safety of a green coffee bean extract in overweight subjects
Obesity: considerations about etiology, metabolism, and the use of experimental models
- Testimonials
"You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio
- The economic impact of obesity in the United States
- Alogliptin: a new addition to the class of DPP-4 inhibitors
- Self-monitoring of blood glucose in noninsulin-treated type 2 diabetes: an overview
- Adipose inflammation: cause or consequence of obesity-related insulin resistance




